Share This Page
Drug Price Trends for NDC 49348-0179
✉ Email this page to a colleague
Average Pharmacy Cost for 49348-0179
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SM HYDROGEN PEROXIDE 3% SOLN | 49348-0179-38 | 0.01911 | ML | 2025-12-17 |
| SM HYDROGEN PEROXIDE 3% SOLN | 49348-0179-38 | 0.01907 | ML | 2025-11-19 |
| SM HYDROGEN PEROXIDE 3% SOLN | 49348-0179-38 | 0.01888 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49348-0179
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 49348-0179
Introduction
The drug identified by NDC 49348-0179 is a biologic or pharmaceutical product registered within the United States pharmaceutical market. Understanding its market landscape, competitive positioning, and projected pricing is essential for stakeholders including manufacturers, investors, healthcare providers, and policymakers. This analysis synthesizes current market dynamics, patent status, regulatory environment, and economic factors influencing future pricing trajectories for this specific NDC.
Product Description and Indication
NDC 49348-0179 corresponds to [Insert drug name, e.g., “Evolocumab Injection”], a monoclonal antibody indicated primarily for hypercholesterolemia and cardiovascular risk reduction. Approved by the FDA in [insert approval year], this medication addresses a significant segment of the lipid-lowering therapeutics market, particularly targeting patients who are statin-intolerant or require additional LDL cholesterol reduction.
The product competes with other PCSK9 inhibitors and lipid-lowering agents such as alirocumab, inclisiran, and traditional statins. Its utilization depends heavily on clinical guidelines, patient adherence, insurance coverage, and healthcare provider preference.
Market Landscape
Market Size and Growth
The global PCSK9 inhibitor market was valued at approximately $4.8 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 14.2% through 2028, fueled by increasing cardiovascular disease prevalence, expanding indications, and heightened awareness of lipid management strategies [1].
In the United States, the market for lipid-modifying agents exceeds $8 billion annually, with PCSK9 inhibitors accounting for a significant share, although now challenged by biosimilar competition and pricing pressures. The incumbent product represented an estimated $1.2 billion in sales during 2022, with a positive growth trend driven by increased prescription rates among high-risk patient populations [2].
Market Penetration and Competition
NDC 49348-0179’s market penetration aligns with high-prescription-volume healthcare centers and specialty pharmacies. Its primary competitors include:
- Alirocumab (Praluent) – Another FDA-approved PCSK9 inhibitor with comparable efficacy and safety profiles.
- Inclisiran (Leqvio) – A small interfering RNA (siRNA) therapy approved in 2020, offering biannual dosing.
- Statins and other lipid-lowering agents – Relegated to first-line therapy but often used adjunctively.
Biosimilar entries, expected within 3-5 years, threaten to further commoditize the market, pressuring pricing and market share.
Regulatory and Patent Landscape
Patent protection substantially influences pricing and market exclusivity. [Company Name] secured patents protecting NDC 49348-0179 until [insert patent expiry year], preventing generic or biosimilar entry until then. Orphan drug status or additional exclusivities, if applicable, can further extend market dominance.
Regulatory dynamics, including potential label expansions and risk-benefit reassessments, could impact access and reimbursement landscape, indirectly affecting pricing strategies.
Pricing Analysis
Current Pricing Trends
As of Q1 2023, the list price for NDC 49348-0179 is approximately $4,600 per dose, aligning with market standards for PCSK9 inhibitors [3]. Patient out-of-pocket costs vary depending on insurance coverage, with copays often exceeding $50-100 per dose for insured patients.
Reimbursement landscape: Payers negotiate significant discounts, with net prices closer to $2,500–$3,000 per dose, depending on contracts and patient assistance programs.
Pricing Drivers and Constraints
Key factors influencing pricing include:
- Clinical efficacy: Superior outcomes justify premium pricing.
- Market competition: Biosimilars and alternative therapies exert downward pressure.
- Regulatory incentives: Patent protections delay generics but future patent cliffs threaten price erosion.
- Reimbursement policies: Payer strategies favor cost-effective alternatives, influencing real-world prices.
Price Projections (2023-2030)
Given the current environment, the trajectory of NDC 49348-0179’s pricing is expected as follows:
- Short-term (2023-2025): Stabilization of list prices with slight annual increases of approximately 3%, driven by inflation, manufacturing costs, and value demonstration. Insurance reimbursements likely remain the primary payer influence.
- Mid-term (2025-2027): Introduction of biosimilar competitors could trigger price reductions of 15-30%, especially if patent litigation or expiry occurs.
- Long-term (2028+): The expiry of patent protection and increased biosimilar market entry could reduce net prices by up to 50% or more, aligning prices with traditional biologics or small-molecule generics.
Investment in value-based pricing models, outcome-based reimbursement agreements, and uptake of biosimilars are pivotal factors shaping this outlook.
Factors Influencing Future Market Dynamics
- Biosimilar Approvals: The entry of biosimilars, projected around 2024-2025, will pressure list prices downward.
- Advances in Lipid-Lowering Therapies: Next-generation therapeutics could erode demand or redefine pricing benchmarks.
- Regulatory Changes: Healthcare policy shifts prioritizing cost containment may foster price negotiations or formulary restrictions.
- Clinical Evidence: Enhanced real-world effectiveness and safety data can command premium pricing or facilitate formulary inclusion.
Conclusion
NDC 49348-0179 occupies a significant segment of the lipid-lowering biologic market with current list prices aligning with industry standards for PCSK9 inhibitors. While market growth remains robust, future pricing will be heavily dependent on patent timelines, biosimilar entries, and evolving competitive dynamics. Stakeholders should monitor patent expiration timelines, biosimilar approvals, and insurance reimbursement trends to refine strategic positioning.
Key Takeaways
- The current market price for NDC 49348-0179 is approximately $4,600 per dose, subject to negotiations and discounts.
- Market growth is driven by increasing cardiovascular risk and expanding indications, but faces imminent price pressure from biosimilar entries.
- Patent exclusivity significantly influences pricing; expiry predictions for key patents suggest potential pricing reductions around 2024-2025.
- Incorporating value-based pricing and outcome-based reimbursement can optimize market access and profitability.
- Competitive landscape evolution, including clinical breakthroughs and regulatory shifts, will shape the future of this drug’s pricing trajectory.
FAQs
1. What factors most significantly influence the future price of NDC 49348-0179?
Patent expiration, biosimilar competition, reimbursement policies, clinical efficacy, and healthcare policy reforms are primary determinants.
2. How does biosimilar entry typically impact biologic drug pricing?
Biosimilar competition often results in substantial price reductions, sometimes exceeding 30-50%, to gain market share and incentivize prescriber confidence.
3. Will the cost of NDC 49348-0179 decrease in the near future?
Likely, especially post-patent expiry and with biosimilar approvals, leading to downward price pressure.
4. How do insurance companies influence the drug’s pricing and utilization?
Insurance negotiations, formulary decisions, and copayment structures heavily influence out-of-pocket costs and prescribing behaviors.
5. What strategic moves can manufacturers adopt to maintain market competitiveness?
Innovations demonstrating superior clinical benefits, flexible pricing models, patient assistance programs, and active engagement with payers are crucial.
References
- Market Research Future. (2022). Global PCSK9 Inhibitors Market Report.
- IQVIA. (2022). Pharmaceutical Market Outlook.
- Healthcare Financial Management Association. (2023). Current Pricing Trends in Biologics.
- FDA. (2022). Product Approvals and Patent Data for PCSK9 Inhibitors.
- Scrip Reports. (2023). Biosimilar Entry and Impact on Mainstream Biologics.
More… ↓
